Skip Navigation

European Journal of Heart Failure 2006 8(4):428-432; doi:10.1016/j.ejheart.2006.02.012
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cokkinos, D. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cokkinos, D. V.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society of Cardiology

Efficacy of antithrombotic therapy in chronic heart failure: The HELAS study

Dennis V. Cokkinosa,b,*, George C. Haralabopoulosb, John B. Kostisc, Pavlos K. Toutouzasa and for the HELAS investigators

a Cardiology Department, Hippokrateio Hospital, University of Athens Athens, Greece
b 1st Cardiology Department, Onassis Cardiac Surgery Center Athens, Greece
c UMDNJ-Robert Wood Johnson Medical School New Brunswick, USA

* Corresponding author. Cardiology Department, Hippokrateio Hospital, University of Athens, Athens, Greece.


   Abstract

Background: It is not clear if long-term antithrombotic treatment has a beneficial effect on the incidence of thromboembolism in chronic heart failure (CHF). The HELAS study (Heart failure Long-term Antithrombotic Study) is a multicentre, randomised, double-blind, placebo-controlled trial to evaluate antithrombotic treatment in patients with CHF.

Methods: 197 HF patients (EF <35%) were enrolled. Patients with Ischaemic Heart Disease were randomised to receive either aspirin 325 mg or warfarin. Patients with Dilated Cardiomyopathy (DCM) were randomised to receive either warfarin or placebo.

Results: Analysis of the data from 312 patient years showed an incidence of 2.2 embolic events per 100 patient years, with no significant difference between groups. The incidence of myocardial infarction, hospitalisation, exacerbation of heart failure, death and haemorrhage were not different between the groups. No peripheral or pulmonary emboli were reported. Echocardiographic follow-up for 2 years showed an overall increase in left ventricular ejection fraction from 28.2±6 to 30.3±7 p<0.05, which was most obvious in patients with DCM taking warfarin (EF 26.8±5.3 at baseline, 30.7±10 at 2 years, p<0.05).

Conclusions: (1) Overall embolic events are rare in heart failure regardless of treatment. (2) Treatment does not seem to affect outcome.

Key Words: Heart failure treatment • Aspirin • Anti-thrombotic treatment • Anticoagulants

Received December 22, 2004; Revised July 22, 2005; Accepted February 27, 2006


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
ICVTSHome page
M. Nagashima, S. Takano, E. Yamamoto, and T. Higaki
Migration of left ventricular thrombus causing abdominal aortic embolism during cardiac surgery in a child with severe left ventricular dysfunction
Interactive CardioVascular and Thoracic Surgery, May 1, 2009; 8(5): 596 - 598.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
C. Meune, K. Wahbi, Y. Fulla, A. Cohen-Solal, D. Duboc, I. Mahe, G. Simoneau, J.-F. Bergmann, S. Weber, and S. Mouly
Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors
Eur J Heart Fail, February 1, 2007; 9(2): 197 - 201.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.